Printer Friendly

Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China.

M2 PHARMA-May 10, 2019-Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

(C)2019 M2 COMMUNICATIONS

- Chinese biotechnology company Clover Biopharmaceuticals has received Clinical Trial Application approval from the Chinese National Medical Products Administration to conduct clinical trials in China with SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, for the treatment of cancer patients with intracavitary malignancies, the company said.

A phase I clinical trial for malignant ascites is planned to initiate in China this year.

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercialising biologic therapies, with a focus on oncology and autoimmune diseases.

Clover is utilizing its proprietary Trimer-Tag(c) technology platform to develop novel biologics targeting trimerization-dependent pathways.

Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Trimer-Tag(c) is a drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Many major disease targets are trimerization-dependent such as the tumor necrosis factor superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells.

Clover is using Trimer-Tag(c) technology to create trimerized fusion proteins that are able to effectively target these previously undruggable pathways.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 10, 2019
Words:217
Previous Article:Mati Therapeutics Phase II Nepafenac Evolute Clinical Trial Results Show Significant Post-Operative Pain Reduction in Cataract Surgery Patients.
Next Article:European Commission Approves Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |